- Home
- BBIO
as 07-26-2024 4:00pm EST
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Upcoming Earnings Alert:
Get ready for potential market movements as BridgeBio Pharma Inc. BBIO prepares to release earnings report on 01 Aug 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 5.2B | IPO Year: | 2019 |
| Target Price: | $46.83 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $44.32 | Next Earning Date: | 08-01-2024 |
| Revenue: | $218,597,000 | Revenue Growth: | 181.05% |
| Revenue Growth (this year): | 4043.82% | Revenue Growth (next year): | -43.60% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scott Randal W. | BBIO | Director | Jun 3 '24 | Sell | $28.68 | 800 | $22,947.52 | 5,700 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Jun 3 '24 | Sell | $29.48 | 200 | $5,895.00 | 5,500 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Jun 3 '24 | Sell | $31.30 | 1,500 | $46,950.00 | 4,000 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Mar 1 '24 | Sell | $34.00 | 2,500 | $85,000.00 | 6,500 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Feb 15 '24 | Sell | $37.75 | 2,915 | $110,041.25 | 1,764 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Jan 16 '24 | Sell | $37.97 | 2,915 | $110,682.55 | 1,764 | SEC Form 4 |
| MCCORMICK FRANK | BBIO | Director | Dec 26 '23 | Sell | $42.06 | 100,000 | $4,206,000.00 | 627,689 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Dec 18 '23 | Sell | $40.00 | 2,000 | $80,000.00 | 9,000 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Dec 15 '23 | Sell | $36.12 | 2,915 | $105,289.80 | 1,764 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Dec 1 '23 | Sell | $28.50 | 1,000 | $28,500.00 | 12,500 | SEC Form 4 |
| Scott Randal W. | BBIO | Director | Dec 1 '23 | Sell | $30.00 | 1,500 | $45,000.00 | 11,000 | SEC Form 4 |
| Kumar Neil | BBIO | CEO and President | Nov 16 '23 | Sell | $29.10 | 51,352 | $1,494,127.52 | 4,813,397 | SEC Form 4 |
| Kumar Neil | BBIO | CEO and President | Nov 16 '23 | Sell | $29.55 | 200 | $5,910.00 | 4,813,197 | SEC Form 4 |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Nov 16 '23 | Sell | $29.10 | 22,685 | $660,058.64 | 36,710 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Nov 15 '23 | Sell | $30.00 | 2,915 | $87,450.00 | 1,764 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Dec 28 '21 | Buy | $13.18 | 1,891 | $24,923.38 | 1,891 | SEC Form 4 |
| Valantine Hannah | BBIO | Director | Dec 28 '21 | Buy | $12.68 | 1,542 | $19,552.56 | 3,433 | SEC Form 4 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
BridgeBio Pharma Names New COO
GlobeNewswire
3 days ago
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire
21 days ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
a month ago
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
MT Newswires
a month ago
BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial
GlobeNewswire
a month ago
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
GlobeNewswire
2 months ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.